Introduction
Aluminum (Al) is a toxicant to the central nervous, skeletal and hematopoietic systems (Krewski et al., 2007) . The primary source of oral Al exposure in the U.S. for the typical human is foods, representing ~ 95% of daily oral intake; drinking water contributes ~ 1 to 2% (WHO, 1997; ATSDR, 1999; Krewski et al., 2007) . These typically provide a total of ~ 4000 to 9,000 µg Al/day. Consumption of antacids can provide up to 5,000,000, inhalation from environmental and industrial air 4 to 20 and up to 25,000, and antiperspirant use up to ~ 70,000 µg/day. Injected Al in vaccines and allergy immunotherapy can provide 1 to 8 and 7 to 40 µg/ day, respectively, and probably complete absorption . Some people may have further Al exposures, e.g., occupational (Elinder et al., 1991) , Alcontaminated dialysis fluid (Alfrey et al., 1976) , alum instillation into a hemorrhaging urinary bladder (Phelps et al., 1999) and illicit drug abuse, including intravenous self-injection of methadone prepared in Al cookware (Friesen et al., 2006; Yong et al, 2006; Exley et al, 2007) . Although tobacco contains considerable Al, ~ 500 to 2000 µg/cigarette, < 0.02 to 0 .075 µg appeared in the smoke from one cigarette (Cogbill and Hobbs, 1957; Exley et al., 2006) . Even if 100% bioavailable, when compared to oral Al intake of 5000 µg/day from diet that is 0.25% bioavailable delivering 12.5 µg to systemic circulation, a cigarette would deliver only ~ 0.4% as much. It was suggested that drinking water provides a disproportionate contribution to total Al absorbed from the gastrointestinal tract because it is largely uncomplexed in water, whereas organic ligands such as phytates and polyphenols in food were suggested to complex Al and inhibit its oral absorption (Martyn et al., 1989) . This notion has been followed by ≥ 12 epidemiological studies since 1989 assessing the association between Al in drinking water and cognitive impairment, dementia and Alzheimer's disease (AD) (Krewski et al., 2007) . Many showed a significantly higher odds ratio for dementia among study subjects living in areas where the drinking water had a higher Al concentration. However, there is no evidence that drinking water is the major source of systemic Al for the typical person. The study in this report was aimed at testing this notion.
If Al bioavailability from water is not considerably greater than from food, studies assessing a putative link between Al in drinking water and AD might be misfocused, and studies investigating a possible association between Al in food and cognitive impairment, dementia and AD might be more relevant. There is only one published study assessing a putative link between dietary Al intake in food and AD (Rogers and Simon, 1999) . In 23 matched sets of residents of a geriatric center with and without AD, the adjusted odds ratio for several food groups, including baked goods and cheese, was elevated. However, due to the very small sample size, most results did not reach statistical significance.
Adult daily dietary Al intake in the U.K. and U.S. has been estimated to be 3.9 and 7 to 9 mg (depending on age and sex), respectively (UK-MAFF, 1993; Pennington and Schoen, 1995) . There have been at least 12 other estimates of adult dietary Al intake published in the past 10 years from other countries. Most reported equal or less daily Al intake than in the U.S. The lower daily Al intake in some countries, such as in Europe, has been attributed to less use of Al as a food additive (Müller et al., 1998) .
Different food sources contribute variable amounts of Al to the human diet (Pennington, 1987; UK-MAFF, 1993; Lopez et al., 2002) . Sodium aluminum phosphates (SALPs) are generally recognized as safe (GRAS) FDA-approved food additives that contribute the greatest amount of Al to the diet (Katz et al., 1984; Humphreys and Bolger, 1997; Saiyed and Yokel, 2005) . Basic SALP is one of many "emulsifying salts" added to process cheese, cheese food and cheese spread which react with and change the protein of cheese to produce a smooth, uniform film around each fat droplet to prevent separation and bleeding of fat from the cheese. This produces a soft texture, easy melting characteristics and desirable slicing properties (Ellinger, 1972) . Basic SALP is permitted by the FDA up to 3% in pasteurized process cheese (21CFR133.169), pasteurized process cheese food (21CFR133.173), and pasteurized process cheese spread (21CFR133.179). The FDA regulates basic SALP as an emulsifier that is GRAS (FASEB, 1975) . Basic SALP is also permitted up to 3.5% in cheese in Canada (Food and Drugs Act -Food and Drug Regulations, Part B, Division 16; http://www.hc-sc.gc.ca/fn-an/alt_formats/hpfb-dgpsa/pdf/legislation/e_c-tables.pdf), as potassium aluminum silicate up to 10 g/kg in Australia and New Zealand ( http://www.foodstandards.gov.au/_srcfiles/FSC_Amend_Standard_1_2_4_Labelling_of_Ingred_v91.pdf#search=% ), but evidently not by the E.U. or U.K., although other Al-containing compounds are permitted in cheese, up to 10 g/kg (E 554, E 555, E 556 and E 559) (http://ec.europa.eu/food/fs/sfp/addit_flavor/flav11_en.pdf http://ec.europa.eu/food/fs/sc/scf/reports/scf_reports_40.pdf). Studies of the Al content of unprocessed cheese generally reported < 10 mg Al/kg (Delves et al., 1989; Schenk et al., 1989; Müller et al., 1998; Dolan and Capar, 2002) . In contrast, some process cheeses (often marketed as sliced, American) were reported to contain 695 (Gormican, 1970) , 411 (Pennington, 1989) , 320 (Pennington and Schoen, 1995) , 1440 (Greger, 1985) , and 470 mg Al/kg (Saiyed and Yokel, 2005) . The cheese of frozen pizzas that contained basic SALP was reported to contain up to ~ 750 mg Al/kg, whereas ready-to-eat restaurant pizza cheese had < 10 mg Al/kg (Saiyed and Yokel, 2005) . Basic SALP (Na 8 Al 2 (OH 2 )((PO) 4 ) 4 ) has a 4:1:2 ratio of Na:Al:P. It is ~ 10% Al.
Concern about the safety of the addition of Al in foods was expressed long ago (Gies, 1911) and again recently. Department of the Planet Earth (a non-profit NGO) petitioned the FDA in 2005 to rescind the GRAS status for Al-based food additives (http://www.deptplanetearth.com/aboutus.html). A Joint FAO (Food and Agriculture Organization of the UN)/WHO Expert Committee on Food Additives established a revised provisional tolerable weekly intake (PTWI) for all Al compounds in foods, including additives, of 1 mg/kg/bw. The Expert Committee noted the potential for Al to effect the reproductive and developing nervous system at lower doses than those used to establish the previous PTWI of 7 mg/kg/bw (FAO/WHO, 2006) . The Committee commented on the "probable lower bioavailability of the less soluble Al compounds present in food" and that the PTWI was likely to be exceeded by some population groups, particularly children, who regularly consume foods containing Al additives.
To better understand the relative contribution of food and water to human Al intake, it has been noted that research needs to be conducted to more accurately determine the oral bioavailability of Al from the typical diet (Personal communication from Amal M. Mahfouz, US EPA). Oral bioavailability (fractional absorption) is the amount absorbed compared to the amount administered. For Al, systemic bioavailability, the fraction that reaches systemic circulation from which it has access to the target organs of its toxicity, is most relevant.
Several studies have estimated oral Al bioavailability under conditions that model Al consumption in drinking water. Oral Al bioavailability from alum-treated water obtained from a municipal water treatment facility was estimated to be 0.36% in a study of 21 humans (Stauber et al., 1999) . Two studies in humans that utilized 26 Al but only two subjects each, therefore providing limited confidence in the results, estimated oral Al bioavailability to be 0.1 and 0.22%, respectively (Hohl et al., 1994; Priest et al., 1998) . The above studies estimated oral Al absorption based on urinary Al excretion. However, not all absorbed Al appears in the urine, which accounts for ~ 98% of excreted Al, or the bile, which accounts for most of the other 2%. Some absorbed Al is retained. Secondly, if Al in the urine is used as an endpoint for absorption, the experimenter would have to continue to determine this endpoint until sure that all had been eliminated. There are a few reports where the amount of Al in the urine was corrected for these 2 factors (not all absorbed Al appears in the urine and the study was not conducted long enough to collect all excreted Al). Stauber et al. (1999) multiplied the amount of Al that appeared in the urine in the 24 hours after oral Al consumption by 2.2, to correct for partial Al elimination (only 72% of intravenously injected Al was found in the urine after 7 days (Talbot et al., 1995) and only 62 to 63% of the Al in the urine recovered in 7 days was found in the first day (Priest, 1993) ). Stauber et al only collected urine for 24 hours. They did not correct for absorbed Al that was retained. The large correction factor reduces confidence in the accuracy of the reported oral bioavailability. Hohl et al. (1994) took into consideration that only about 80% of injected Al was found in the urine after 10 days and commented that the amount of Al excreted in the urine after their 4 days of collection was probably not great. They provided an estimate of the percentage of Al absorbed as 0.1%, not presenting this as a precise value. In two studies that used the methods employed in the present report oral Al bioavailability in the rat averaged 0.28% and 0.29% Zhou and Yokel, 2006) .
The bioavailability of hydrophilic substances that are not well absorbed can be determined by comparing the areas under the concentration × time curve (AUC) for the test substance given po and iv. This approach was used in the only study reported to date that estimated oral Al bioavailability from a specific food product. In that study, oral Al bioavailability in rats that ate ~ 1 gm of biscuit containing [ 26 Al]-labeled acidic SALP averaged ~ 0.12% (Yokel and Florence, 2006) . This approach was used in the present study in which the po dose was given as 26 Al and the iv dose as 27 Al to the same subject at the same time. Compared to an experimental design where a rat receives the two doses at different times, this method reduces variability by concurrently determining the AUCs from the po and iv doses in the rat. To determine the oral bioavailability of Al from basic SALP in a process cheese, [ 26 Al]-containing basic SALP was prepared and incorporated into a process cheese that was presented to rats for their consumption. Blood was repeatedly obtained from the rats in which 26 Al and total Al (essentially 27 Al) were analyzed by accelerator mass spectrometry (AMS) and electrothermal atomic absorption spectrometry (ETAAS), respectively. The absence of significant 26 Al in the environment or in normal biological organisms avoids the interference of endogenous Al in studies of Al pharmacokinetics. When 4 mg of 27 Al is added to 26 Al-containing samples to establish the 27 Al concentration, as in the present study, AMS can measure the 26 Al: 27 Al ratio with a detection limit of ~ 10 −14 (~ 4 × 10 −17 g of 26 Al) or ~ 1,000,000 atoms. This enables the conduct of pharmacokinetic studies of Al at physiological concentrations, as conducted herein. In addition to oral bioavailability, two other standard pharmacokinetic parameters, the time to maximum serum 26 Al concentration of (T max ) and the maximum serum 26 Al concentration of (C max ), were determined (Bauer, 2006) . These methods enabled us to address the objectives of the present study: to determine the oral bioavailability of Al from processed cheese that contains basic SALP, at a concentration relevant to its use in cheese, and to determine standard pharmacokinetic parameters of the absorbed Al.
Methods

Materials
Details of the preparation and characterization of the basic SALP containing 26 Al (basic 26 Al-SALP) were described . 26 Al was provided by the Purdue Rare Isotope Measurement Laboratory (PRIME Lab), supplied in 0.06 N HCl containing 13.78 nCi (725 ng) 26 Al/ml and with a 34:1 27 Al: 26 Al ratio. Briefly, Al-containing sodium aluminate was prepared then characterized by elemental analysis of Na and Al and Raman spectroscopy. It was incorporated into the synthesis of basic SALP (CAS [7785-88-8], INS No. 541) by the method of (Bell, 1973) . The basic SALP was characterized by near infrared spectroscopy, xray powder diffraction spectroscopy, and elemental analysis of Na, Al and P. 26 Al-containing basic SALP was concurrently and identically prepared. Non-26 Al-containing basic SALP was used to dilute 26 Al-containing samples to ~ 1 nCi 26 Al/15 or 30 mg basic SALP. The 26 Albasic SALP was incorporated into a process cheese. These two concentrations (1.5 and 3% basic SALP) were studied to ascertain if there was concentration-dependent absorption and to stay within the maximum permitted use level of 3 to 3.5% for basic SALP as an emulsifying agent in process cheese. Cheese containing 26 Al-basic SALP was prepared from 8.8 gm aged
(1 year) Kroger brand sharp cheddar cheese, ~ 1 gm water and 150 or 300 mg basic SALP (to make 1.5 and 3% SALP in cheese).
To produce a moderately firm cheese product the ingredients were heated in a microwave oven for 13 sec, stirred for 15 sec, heated for another 5 sec, stirred 10 sec and some samples further heated and stirred. Identical process cheeses were prepared containing 1.5, 2.25 and 3% SALP without 26 Al. They were used to condition the rats to eat the process cheese and to dose the control (non-26 Al-treated) rats, as described below.
The 26 Al concentration in the process cheese was determined as follows. Three samples, ~ 30 to 35 mg, of the 1.5 and 3% 26 Al-basic SALP were transferred to 7 ml screw cap Teflon® Tuftainers® and 4 mg Al (Sigma ICP/DCP standard) added, and the sample dried. Samples were then digested in 1.5 ml 1M KOH and sonicated to create a solution, as described (Saiyed and Yokel, 2005) , serially diluted 10-fold 4 times, and an aliquot transferred to a porcelain crucible and 4 mg of Al standard added. This was slowly heated to 1000 °C in a muffle furnace to convert the Al to Al oxide that was analyzed by AMS, as described below. The process cheeses containing 1.5 and 3% basic 26 Al-SALP had 1.80 nCi (95.0 ng) and 1.57 nCi (82.6 ng) 26 Al/gm, respectively.
Animals
This study used 15 male Fisher 344 rats, weighing 272 ± 11g (mean ± SD) that were housed individually prior to the study in the University of Kentucky Division of Laboratory Animal Resources facility. Animal work was approved by the University of Kentucky Institutional Animal Care and Use Committee. The research was conducted in accordance with the Guiding Principles in the Use of Animals in Toxicology.
Experimental procedures
The rats were acclimated to a 10% protein diet designed to minimize food retention in the stomach (Harlan Teklad 95215). They had food access from 08:00 to 18:00 h daily for at least 5 days prior to the determination of oral Al bioavailability. This diet was shown to result in the absence of food in the stomach 14 h after its withdrawal when fecal recycling (coprophagia) was prevented by a fecal collection cup, as described and used in this study . Drinking water was freely available throughout the study except for the period from 14 h before to 4 h after presentation of cheese containing basic SALP.
The rats were conditioned to eat 1 g of process cheese containing 1.5% and 3% basic SALP (containing no 26 Al) on alternate days which was presented, with access to 2 ml of MilliQ polished water, 14 h after diet removal daily for at least 4 days.
Rats that readily ate the cheese within 15 min were surgically prepared 1 day prior to oral dosing with two venous cannulae introduced into the femoral veins. They terminated in the vena cava. One cannula was used for iv administration, the other for blood withdrawal. The former terminated down-stream of the latter. The amount of cheese containing 26 Al-basic SALP that was consumed was determined by pre-weighing the presented cheese then rigorously recovering from the rat's cage 30 min later the uneaten cheese, which was weighed. Calculations were based on the weight of consumed cheese.
The rats were randomly assigned to be given 1 g process cheese containing 1.5 or 3% basic 26 Al-SALP (n = 6/group), in the absence of food in the stomach. Three control rats were included to document 26 Al contamination. They received process cheese containing 2.25% basic SALP (n=2) or intragastric administration of 1 ml of water (n=1) without 26 Al. They served as monitors for 26 Al contamination. The rats were studied in pairs that received the same 27 Al infusion but different oral treatments.
Oral Al bioavailability was determined in the un-anesthetized rat. Oral bioavailability was determined using a modification of the standard method of comparing the areas under the concentration × time curve (AUC). To enable concurrent administration of the oral and iv Al dose, the tracer 26 Al was used as the oral dose and 27 Al for the iv dose. To give a large enough bolus iv dose of 27 Al that would be significantly above the normal endogenous Al concentration in serum for a long enough period of time to determine its AUC would require a dose that would exceed the transferrin binding capacity for Al (~ 1350 µg Al/L). Therefore the chemical species of the 27 Al in serum would be different (not all Al-transferrin, but for the Al beyond the transferrin binding capacity probably Al citrate) and might be handled differently than the 26 Al that is absorbed and could bind to transferrin after enough of the 27 Al had been cleared to free up binding sites on transferrin. Therefore, we replaced the iv bolus dose with an iv infusion to generate a 27 Al serum concentration significantly above the endogenous Al concentration (so the Al in the serum could be attributed to the 27 Al infusion [iv dose]) but below the transferrin binding capacity. In summary, dose iv was replaced by 27 Al infusion rate × 27 Al infusion duration, as reported in Data analysis.
The rat was iv infused at 100 µg 27 Al/kg/h to produce an estimated 500 µg Al/l in blood plasma for the 27 Al dose, as described . To accomplish this in the present study, AlK(SO 4 ) 2 was infused from 14 h prior to 60 h after oral dosing. Blood was withdrawn 1 h prior to and 0, 1, 2, 4, 8, 24, 36, 48 and 60 h after oral dosing. The withdrawn blood (0.3 ml for the −1 to 4 h samples, 0.5 ml for the 8 h sample, 2.1 ml at 24 h and 4.1 ml at 36 and 48 h), was replaced by an equal volume of injected saline. Additionally, the rats had access to free water and food (10% protein diet) beginning 4 h after dosing. The 60-h blood sample was obtained by anesthetizing the rat and exsanguination from a femoral cannula and then the heart. Serum was obtained for 26 Al and 27 Al analysis. Blood urea nitrogen (BUN) and creatinine were determined in the 60 h sample.
Analysis of total Al by electrothermal atomic absorption spectrometry (ETAAS)
This was conducted as described (Yokel and Florence, 2006) .
Analysis of 26 Al by accelerator mass spectrometry (AMS)
The procedures were as described . A serum QC sample was included with each of the four batches of processed samples. All results were within 10% of the mean of the 5 initial replicates determined when these QC samples were prepared.
Data analysis
A criterion for acceptance of post-treatment serum 26 Al concentrations considered to be reliably above pre-treatment serum values was established as > 2 SD above the mean pretreatment serum 26 Al concentration. This criterion was 0.34 fg 26 Al/ml. Values below this criterion are not presented graphically and were not used in the data analysis. This criterion was met by all of the samples from the 26 Al-treated rats. The initial and 2 nd half-lives of 26 Al elimination, determined using RSTRIP (Fox and Lamson, 1989) , were not different between the two treatment groups, therefore they were combined. The mean initial and 2 nd half-lives were 4.4 and 7.2 h, respectively. Therefore, blood was obtained for > 3 half-lives, sufficient time to determine the AUC of the 26 Al. Each subject's pre-treatment serum 26 Al concentration was subtracted from its post-treatment values. Oral 26 Al bioavailability (F) was calculated as follows and expressed as a percent:
Time to maximum serum 26 Al concentration (T max ) and the maximum concentration (C max ) were calculated using RSTRIP (Fox and Lamson, 1989) .
Unpaired two-tailed t-tests (Mann Whitney tests when the variance was dissimilar) were used to test for differences in Al oral bioavailability, T max and C max from the 1.5% compared to 3% basic SALP. When not statistically significantly different, the combined basic SALP results were compared to acidic SALP in biscuit and water, which were previously conducted (Yokel and Florence, 2006) . A difference of P < 0.05 was accepted as statistically significant.
Results
The rats given cheese containing 26 Al-SALP consumed 0.44 to 1.05 (mean = 0.87) gm cheese. Each rat's serum 26 Al results were normalized to its 26 Al dose. The BUN and serum creatinine values ranged from 7.5 to 17.9 and from < 0.2 to 0.5 mg/dl, well within normal limits (< 30 and 1 mg/dl, respectively). Serum 26 Al concentration in all but one rat prior to 26 Al (or 26 Al vehicle) dosing ranged from 0 to 0.4 (mean = 0.12) fg/ml. Initial samples from one control rat were contaminated. Its pre-treatment and first 4 post-treatment samples ranged from 0.6 to 12.1 fg 26 Al/ml, whereas the 6 th to 9 th samples from this control rat had 0.1 to 0.2 fg 26 Al/ml. Results from this animal have been deleted from the data analysis. The concentration of 26 Al in the 8 samples from each of the other two non-26 Al-treated rats after vehicle dosing ranged from 0 to 0.5 fg/ml (mean = 0.18). The 60 hour sample 26 Al concentration in the 26 Al-treated rats ranged from 0.4 to 3.8 fg/ml. Therefore, contamination appears to have been limited to the 5 samples from the one rat.
Peak serum 26 Al concentration ranged from 55.9 to 159.5 fg/ml after oral 26 Al dosing in 1.5% basic SALP and 28.9 to 146.1 fg/ml after 3% basic SALP. The oral 26 Al dose increased peak serum 26 Al at least 200-fold above mean pre-treatment values. The time courses of serum 26 Al following oral 26 Al dosing for the two treatment groups are shown in Figure 1 . Oral bioavailability (F) was calculated as described in Data analysis as the (sum of 26 Al AUC/ sum 27 Al AUC) × the sampling duration × 27 Al hour infusion rate × body weight × 100%. For one of the rats that consumed cheese containing 1.5% SALP F was 0.12%, calculated from ((the sum of the trapezoidal AUCs for 26 Al [each area calculated as the mean of the 26 Al concentration in the two samples, in fg/ml × the trapezoidal time interval, in hr]/sum of trapezoidal AUCs for 27 Al [each area calculated as the mean of the 27 Al concentration in the two samples, in fg/ml] × the trapezoidal time interval, in hr) × ((the total duration of the serum sampling period, in hr × the 27 Al infusion rate, in fg/kg/hr × the rat's body wt, in kg)/(52630000 × nCi 26 Al/gm cheese × gm cheese consumed by the rat))) × 100, where the sum of the 26 Al AUCs was 2013 fg/ml/hr, the sum of the 27 Al AUCs was 25728 ng/ml/hr, the 27 Al infusion rate was 100000000000 fg/kg/hr, the rat's body weight was 0.254 kg, 52630000 converts nCi 26 Al to fg 26 Al, the cheese had 1.804 nCi 26 Al/gm, the rat consumed 0.97 gm cheese, and 100 converts to percent.
The percentage of the AUC included in the AUC time to last sample /AUC infinity was > 95% in all cases, indicating that samples were collected for sufficient time to adequately determine oral Al absorption. Oral Al bioavailability and the results of RSTRIP analyses (T max and C max ) are shown in Table 1 . Oral bioavailability was marginally significantly different (P = 0.045) between the two groups. Therefore, the results from both treatment groups were compared to results obtained in oral bioavailability studies of Al in water and as acidic SALP in biscuit (Table 1 ). The differences in sum AUC 26 Al, sum AUC 27 Al, Al T max , C max , and C max % dose/ ml serum results from rats consuming 1.5% compared to 3% basic SALP were not statistically significant. Therefore, the differences in these measures from the combined 1.5% and 3% basic SALP data were compared to results from studies of Al absorption from water and as acidic SALP in biscuit (Table 1 ).
Discussion
The present study found a marginally significant effect of the Al concentration on Al bioavailability, for the two concentrations of basic SALP tested, which are in the range of those permitted by the FDA. The difference between the oral bioavailability of the two groups that received 1.5% and 3% basic SALP in cheese was due to the differences in their serum total Al concentration × time profiles (as shown in Table 1 , Sum AUC for iv 27 Al) rather than their serum 26 Al concentration × time profiles (as shown in Table 1 , Sum AUC for po 26 Al and Figure 1 ). As rats were studied in pairs, errors in the 27 Al infusion should be reflected in both rats of the pair. This was not seen. We assume that the 3 rats in the group that ate 1.5% basic SALP in cheese that had higher than average serum 27 Al, and therefore AUCs for iv 27 Al, renally cleared the 27 Al infusion more slowly than most rats. It would be anticipated that the clearance of 26 Al would be similar, concomitantly increasing the AUC for 26 Al. Therefore, these results seem valid. Had the serum 27 Al concentrations in these rats been lower and 26 Al concentrations not different, oral Al bioavailability would have been higher. Therefore, the oral bioavailability of Al from basic SALP incorporated into cheese in the rat appears to be at least 0.1%.
The few studies conducted to date to address the possibility that Al bioavailability is dosedependent have also not resulted in robust findings. Oral Al bioavailability from Al lactate in the rabbit dosed with 108 or 540 mg Al/kg, as Al lactate, was 0.7 and 1.9%, although not significantly different (Yokel and McNamara, 1985) . Urinary 26 Al excretion was higher in two rats after administration of 20 ng of 26 Al with 10 mg 27 Al than with 0.2 mg 27 Al as the chloride (0.032 vs. 0.018% of the 26 Al dose). Serum 26 Al was also higher 1, 5 and 24 hours after the larger total Al dose (Ittel et al., 1993) . These results suggest a positive correlation between aluminium dose and bioavailability. On the other hand, Al absorption into rat blood and tissues after perfusion of the gut with 48 or 64 mM Al chloride at pH 3 was not concentration dependent (Arnich et al., 2004) .
The later T max of Al from basic SALP in process cheese observed in the present study, compared to water, is consistent with the apparent site of Al absorption, the upper intestine and delayed gastric emptying of food compared to water (Froment et al., 1989; Nagy and Jobst, 1994; Whitehead et al., 1997; Arnich et al., 2004) . C max values were lower after oral consumption of 26 Al in process cheese than water, as expected when oral bioavailability is lower and T max is later.
The FDA acceptance of basic SALP as a food additive is based on a review conducted in 1975 (FASEB, 1975) . The reviewers cited unpublished studies that demonstrated a consistent increase in renal microconcretions in female, but not male, rats consuming a diet containing 0.03 to 3% basic SALP (~ 4 to 40 mg Al/kg/day) for 90 days and an in-consistent increase of this endpoint in male and female beagle dogs that consumed basic SALP delivering 7 to 70 mg Al/kg/day. The review panel noted that care should be taken by patients with kidney disease when consuming food containing high levels of Al salts. However, they did not mention dialysis encephalopathy, which has been attributed to Al, or the controversial role of Al in AD. Description of these clinical problems began about 1975. Since that review the contribution of Al from Al cooking utensils to serum Al and urinary Al excretion in patients with chronic renal insufficiency was demonstrated (Lin et al., 1997 ) and numerous studies have described toxic endpoints of Al exposure (Krewski et al., 2007) .
Some studies have been conducted to assess potential toxicity from basic SALP. A study was conducted by Stauffer Chemical Company in male rats fed their basic SALP-containing products. The treatment groups ate feed for 28 days containing: 3% KASAL (1866 mg Al/kg diet; ~ daily dose 141 mg/kg bw), 0.7% KASAL II (908 mg Al/kg diet; ~ daily dose 67 mg Al/ kg bw), 30,000 ppm KASAL II (3761 mg Al/kg diet; ~ daily dose 288 mg Al/kg bw), 14,470 ppm Al hydroxide as a positive control (4034 mg Al/kg diet; ~ daily dose 302 mg Al/kg bw), or the basic (control) diet (66 mg Al/kg diet; ~ daily dose 5 mg Al/kg bw) (Hicks et al., 1987) . Other than a significant increase of serum sodium, no significant effects were seen in bone Al, gross autopsy, histopathology, food consumption, hematology, clinical chemistry or organ weight. A study was conducted in dogs fed diets containing KASAL that produced daily mean Al intakes of ~ 10, 25, or 78 mg Al/kg for 26 weeks, compared to a control diet delivering 4 mg Al/kg/day (Pettersen et al., 1990) . The highest dose of Kasal resulted in a sharp, 1.5 week decrease in food consumption and body weight in males, a decrease in testis weight, seminiferous tubule germinal cell degeneration and atrophy, hepatocyte vacuolation, and tubular-glomerularnephritis. There were no significant effects on serum chemistry, hematology, urinalysis or bone or brain Al, except for a significant increase of brain Al in female dogs consuming the highest Al containing diet. Neither of these studies addressed bioavailability.
There have been studies to estimate oral Al bioavailability from foods. A project was commissioned to determine the relative uptake of Al in many foods (UK-MAFF, 1993) . However, the methods did not enable determination of bioavailability and the trial foods did not contain cheese (UK-MAFF, 1993) . Al bioavailability from diets containing ~ 5 mg Al daily was estimated, based on urinary Al excretion compared to dietary Al intake, to be 0.78% in young human males (Greger and Baier, 1983) . However, cheese was not included in this study nor in a study by (Stauber et al., 1999) who estimated Al bioavailability from drinking water and food in humans to be comparable from these two sources, ~ 0.3%. Oral Al bioavailability from food has been estimated to be ~ 0.1% based on average daily urinary Al excretion compared to average daily Al intake from food (Powell and Thompson, 1993; Priest, 1993; Nieboer et al., 1995) . The only reported study that determined the bioavailability of Al from a specific food used similar methods to the study reported herein and found it to be ~ 0.1% from acidic SALP incorporated into biscuit (Yokel and Florence, 2006) .
In summary, the present estimate of oral Al bioavailability from a dietary component suggests modestly lower or comparable oral Al bioavailability from food than previously reported in studies of water, conducted in the human and rat (Introduction). The results of this study of oral Al bioavailability from basic SALP in a process cheese suggest ~ 0.1 to 0.3% of the Al was orally absorbed. A prior study and a recent replication of that study, using the same methods Zhou and Yokel, 2006) , suggested ~ 0.3% of Al was orally absorbed from water. Other substances in drinking water might alter Al. For example, citrate doubled Al absorption from water (Zhou et al., 2008) . A comparison of the arithmetic products of the absorbed percentage of Al times their contribution to the diet suggests food typically provides at least 90% of dietary Al that reaches systemic circulation. This is based on consumption of 5 to 10 mg of Al in the diet × 0.1 to 0.3% absorption, delivering 5 to 30 µg of Al to systemic circulation daily vs. consumption of 0.1 mg Al daily in drinking water × up to 0.6% absorption, delivering up to 0.6 µg of Al to systemic circulation daily. These results suggesting food is a more important source of absorbed Al than is drinking water, as noted in the Introduction. This suggests that further study of a potential link between orally consumed Al in food and cognitive deficits may be more appropriate than studies of Al in drinking water. Concentration of 26 Al in serum versus time after consumption of basic 26 Al-SALP in a process cheese containing 1.5% (square) or 3% (triangle) basic SALP. The values are mean ± SD from 6 rats in each group.
